Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison - PubMed
a day ago
- #MC4R deficiency
- #obesity treatment
- #GLP-1 analogs
- GLP-1 analogs (semaglutide, tirzepatide, retatrutide) tested for efficacy in MC4R-deficient obesity.
- MC4R is crucial for regulating feeding behavior and energy homeostasis via POMC-MC4R and leptin-MC4R pathways.
- Study conducted on MC4R knockout mice over 21 days to compare GLP-1 analog effects.
- Body weight reduction: semaglutide (19.7%), tirzepatide (31.6%), retatrutide (24.1%).
- All analogs significantly suppressed fat and lean mass, improved metabolic markers (insulin, HOMA-IR, cholesterol).
- GLP-1 analogs reduced liver damage markers (AST, ALT) and liver hypertrophy.
- Suppressed fatty acid synthesis genes but no effect on inflammation-related genes.
- Tirzepatide uniquely decreased respiratory quotient (RQ) in MC4R KO mice.
- Findings support GLP-1 analogs as potential treatments for MC4R-POMC pathway deficiencies.
- MC4R KO mice validated as a reliable model for obesity research.